Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001104659-26-065876
Filing Date
2026-05-26
Accepted
2026-05-26 06:00:54
Documents
6

Document Format Files

Seq Description Document Type Size
1 DEFM14A tm2612585-2_defm14a.htm DEFM14A 2130417
2 GRAPHIC lg_cumberland-4clr.jpg GRAPHIC 15463
3 GRAPHIC lg_velocity-4c.jpg GRAPHIC 6000
4 GRAPHIC sg_velocity-bw.jpg GRAPHIC 6676
5 GRAPHIC px_26cumberlandproxy1pg01-bw.jpg GRAPHIC 357820
6 GRAPHIC px_26cumberlandproxy1pg02-bw.jpg GRAPHIC 327341
  Complete submission text file 0001104659-26-065876.txt   3114476
Mailing Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE TN 37203
Business Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 621765329 | State of Incorp.: TN | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-33637 | Film No.: 261015778
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)